| Bioactivity | Simmitecan hydrochloride, a 9-substituted lipophilic Camptothecin (HY-16560) derivative, is a potent topoisomerase I inhibitor. Simmitecan hydrochloride is an anticancer agent[1][2]. |
| Invitro | Simmitecan hydrochloride 对 CYP2D6 有弱抑制作用 (IC50: 32.9 μM)，对 CYP3A4 有中等抑制作用 (IC50: 8.95 μM)[2]。 |
| In Vivo | Simmitecan hydrochloride (3.75、7.5 和 15 mg/kg, SD 大鼠, 静脉推注) 显示平均消除半衰期 t1/2 约为 1.4 小时[2]。 |
| Name | Simmitecan hydrochloride |
| CAS | 1247847-78-4 |
| Formula | C34H39ClN4O6 |
| Molar Mass | 635.15 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rini B, et al. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. Ann Oncol. 2014 Sep;25(9):1794-1799. [2]. Hu ZY, et al. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals. Acta Pharmacol Sin. 2013 Nov;34(11):1437-48. |
Simmitecan hydrochloride
CAS: 1247847-78-4 F: C34H39ClN4O6 W: 635.15
Simmitecan hydrochloride, a 9-substituted lipophilic Camptothecin (HY-16560) derivative, is a potent topoisomerase I inh
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.